GLP-1 Drug Exenatide Nearly Doubled Smoking Quit Rates When Added to the Nicotine Patch
Adding the GLP-1 drug exenatide to the nicotine patch nearly doubled quit rates and reduced post-cessation weight gain by 5.6 pounds in a pilot trial of overweight smokers.
Quick Facts
What This Study Found
When added to the nicotine patch, exenatide (a GLP-1 receptor agonist) nearly doubled smoking quit rates: 46.3% of the exenatide group achieved abstinence versus 26.8% on placebo (risk ratio 1.70, posterior probability 96.5%). Exenatide also reduced cravings in the overall sample and withdrawal symptoms among those who quit.
Post-cessation body weight was 5.6 pounds lower in the exenatide group compared to placebo (posterior probability 97.4%), addressing one of the most common barriers to quitting — weight gain. Adverse events were higher in the exenatide group (9.5% vs 2.3%) but the treatment was generally tolerable.
Key Numbers
n=84; 46.3% vs 26.8% abstinence; RR=1.70; 5.6 lbs less weight gain; 2 mg exenatide weekly; 21 mg nicotine patch; 6 weeks; PP=96.5% for abstinence; PP=97.4% for weight; AEs 9.5% vs 2.3%
How They Did This
This was a pilot randomized controlled trial. Eighty-four prediabetic and/or overweight smokers were randomly assigned 1:1 to receive either once-weekly exenatide (2 mg subcutaneous injection) or placebo. All participants also received a 21 mg nicotine patch and brief smoking cessation counseling. Abstinence was verified by expired carbon monoxide levels (≤5 ppm) at 6 weeks. The study used Bayesian statistical analysis to quantify evidence for treatment effects.
Why This Research Matters
Smoking remains the leading cause of preventable death, and current quit medications have modest success rates. This trial is among the first to test a GLP-1 drug for smoking cessation in humans, building on animal studies showing GLP-1 receptor agonists reduce nicotine's rewarding effects. The dual benefit — higher quit rates plus less weight gain — makes this approach especially compelling since fear of gaining weight keeps many smokers from trying to quit.
The Bigger Picture
This trial is part of a growing body of research suggesting GLP-1 drugs affect the brain's reward system beyond just food. Anecdotal reports of reduced interest in alcohol, nicotine, and other substances among GLP-1 users have prompted formal studies. If larger trials confirm these results, GLP-1 agonists could become a new tool in addiction medicine — not just for weight loss and diabetes.
What This Study Doesn't Tell Us
This was a small pilot study with only 84 participants and a short 6-week treatment period. The sample was limited to prediabetic and/or overweight smokers, so results may not generalize to all smokers. Longer follow-up is needed to determine whether quit rates persist. Adverse events were more common with exenatide. The study was not powered for definitive conclusions — larger confirmatory trials are needed.
Questions This Raises
- ?Would newer, more potent GLP-1 drugs like semaglutide show even stronger effects on smoking cessation?
- ?Do the quit-rate benefits persist beyond the 6-week treatment window, or do smokers relapse when the drug is stopped?
- ?What is the mechanism by which GLP-1 receptor activation reduces the rewarding effects of nicotine in the brain?
Trust & Context
- Key Stat:
- 46.3% vs 26.8% quit rate Exenatide plus nicotine patch nearly doubled smoking abstinence compared to patch alone, with 5.6 lbs less weight gain
- Evidence Grade:
- This is a randomized controlled trial, which is a strong study design, but it's a small pilot study (84 participants) with a short 6-week duration. The Bayesian analysis provides strong posterior probabilities but the study was not designed to be definitive. Moderate evidence that warrants larger confirmatory trials.
- Study Age:
- Published in 2021, this is recent and relevant research. It predates the explosion of interest in GLP-1 drugs for non-metabolic conditions but is part of the same trend.
- Original Title:
- Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.
- Published In:
- Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 23(10), 1682-1690 (2021)
- Authors:
- Yammine, Luba(4), Green, Charles E(3), Kosten, Thomas R(2), de Dios, Constanza, Suchting, Robert, Lane, Scott D, Verrico, Christopher D, Schmitz, Joy M
- Database ID:
- RPEP-05896
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Can GLP-1 drugs help you quit smoking?
This pilot study suggests they might. Exenatide, a GLP-1 receptor agonist, nearly doubled quit rates when added to the nicotine patch. Animal studies show GLP-1 drugs reduce nicotine's rewarding effects in the brain, and this is among the first human trials to test that theory. However, larger studies are needed to confirm these early results.
Why do people gain weight when they quit smoking?
Nicotine suppresses appetite and increases metabolism. When people stop smoking, their appetite returns and metabolism slows, leading to an average weight gain of 5-10 pounds. This study found that exenatide — which also suppresses appetite — offset this effect, with quitters gaining 5.6 pounds less than those on placebo.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05896APA
Yammine, Luba; Green, Charles E; Kosten, Thomas R; de Dios, Constanza; Suchting, Robert; Lane, Scott D; Verrico, Christopher D; Schmitz, Joy M. (2021). Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 23(10), 1682-1690. https://doi.org/10.1093/ntr/ntab066
MLA
Yammine, Luba, et al. "Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.." Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2021. https://doi.org/10.1093/ntr/ntab066
RethinkPeptides
RethinkPeptides Research Database. "Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cess..." RPEP-05896. Retrieved from https://rethinkpeptides.com/research/yammine-2021-exenatide-adjunct-to-nicotine
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.